A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2006
10/26/2006	US20060240043 Methods and compositions for treating migraine pain
10/26/2006	US20060240042 genetic vaccines; Gag, Pol, Pro, Tat, Nef, Rev, Vif, Vpr or Env antigens
10/26/2006	US20060240041 PRRSV Vaccines
10/26/2006	US20060240040 Optimized expression of hpv 45 l1 in yeast
10/26/2006	US20060240039 Vaccines
10/26/2006	US20060240038 Cells used as carriers for bacteria
10/26/2006	US20060240036 I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
10/26/2006	US20060240035 Vmp-like sequences of pathogenic borrelia species and strains
10/26/2006	US20060240034 Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
10/26/2006	US20060240033 Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
10/26/2006	US20060240032 Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
10/26/2006	US20060240031 T cell receptor cdr3 sequences and methods for detection
10/26/2006	US20060240030 Anti-hiv immunogenic formulation and process for preparation thereof
10/26/2006	US20060240029 Chlamydia pneumoniae antigens
10/26/2006	US20060240028 Anti-nls substances and uses thereof in nuclear import inhibition
10/26/2006	US20060240027 Conjugated with toxins, enzymes, radioactive compounds, and hematogenous cells; use in staging and diagnosis; treatment of metastasis
10/26/2006	US20060240026 Preventing and/or remedy hematopoietic tumor
10/26/2006	US20060240025 isolated polypeptide encoded by an isolated nucleic acid molecule as antitumor biodrugs; modulation of chemokine, cytokine expression
10/26/2006	US20060240024 T cell regulation
10/26/2006	US20060240023 Apoptosis-associated protein and use thereof
10/26/2006	US20060240022 Factor involved in metastasis and uses thereof
10/26/2006	US20060240021 Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes
10/26/2006	US20060240020 Inhibition of complement activation
10/26/2006	US20060240019 Antagonists of HMG1 for treating inflammatory conditions
10/26/2006	US20060240018 Artificial antibody polypeptides
10/26/2006	US20060240017 IgG4 constant region; antigen-binding Fab' fragment; antibody or antigen binding fragment competitively inhibits binding of A2 to human TNF- alpha , and binds to a neutralizing epitope of human TNF- alpha
10/26/2006	US20060240016 Activity of THAP-family chemokine-binding domains
10/26/2006	US20060240015 Recombinant antibody against human insulin-like growth factor
10/26/2006	US20060240014 Methods and compounds for the treatment of vascular stenosis
10/26/2006	US20060240013 Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
10/26/2006	US20060240012 For treating inflammation and immunopathy; rheumatoid arthritis
10/26/2006	US20060240011 Use of nf-kappa b inhibitors for the treatment of mastitis
10/26/2006	US20060240010 Methods of modulating CD200 receptors
10/26/2006	US20060240009 Liposome composition for improved intracellular delivery of a therapeutic agent
10/26/2006	US20060240008 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
10/26/2006	US20060240007 Method for treating dementia or Alzheimer's disease
10/26/2006	US20060240006 Novel antibody structures derived from human germline sequences
10/26/2006	US20060240005 Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
10/26/2006	US20060240004 Methods for treating tweak-related conditions
10/26/2006	US20060240003 Humanised antibodies to the epidermal growth factor receptor
10/26/2006	US20060240002 Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
10/26/2006	US20060240001 Modulation of P-cadherin mediated adhesion and intracellular signaling is expected to result in decreased proliferation and survival of tumor cells in vivo
10/26/2006	US20060240000 Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound
10/26/2006	US20060239999 Preventive and/or therapeutic drugs for asthma
10/26/2006	US20060239998 Prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII; antihemophilic factor inhibitors; monoclonal cell lines expressing such anti-idiotypic antibodies; monoclonal cell lines expressing such anti-idiotypic antibodies
10/26/2006	US20060239997 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
10/26/2006	US20060239996 ANTIBODIES SPECIFIC FOR UNGULATE PrP
10/26/2006	US20060239991 polypeptide has the biological activity of methionyl tRNA synthetase; for the protection against bacterial infections
10/26/2006	US20060239971 Vectors for regulating gene expression
10/26/2006	US20060239963 Quil a fraction with low toxicity and use thereof
10/26/2006	US20060239962 Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
10/26/2006	US20060239931 Pharmaceutical aerosol composition
10/26/2006	US20060239924 Carrier with a metal binding domain, a metal ion, and an active agent; e.g., polylysine with a polyoxyethylene side chain with a polyalkylenepolyaminepolyacetic acid bonded to a transition metal ion bonded to a protein or nucleotide; drug delivery
10/26/2006	US20060239912 Carrier molecules
10/26/2006	US20060239911 Antibodies with immune effector activity and that internalize in endosialin-positive cells
10/26/2006	US20060239910 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
10/26/2006	US20060239909 Treatment of protein degradation disorders
10/26/2006	DE202005020828U1 New human antibody that is able to bind human CD152 or its antibody fragment, useful for treating tumor disease e.g. lung cancer, skin cancer, bone cancer, uterus cancer, ovarian cancer and stomach cancer
10/26/2006	CA2618721A1 Elimination of heterogeneous or mixed cell population in tumors
10/26/2006	CA2606673A1 Mutant f. tularensis strain and uses thereof
10/26/2006	CA2606180A1 C. perfringens alpha toxoid vaccine
10/26/2006	CA2605964A1 High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
10/26/2006	CA2605507A1 Humanized anti-cd70 binding agents and uses thereof
10/26/2006	CA2605442A1 Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
10/26/2006	CA2605402A1 Antibody neutralizers of human granulocyte macrophage colony stimulating factor
10/26/2006	CA2605321A1 Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
10/26/2006	CA2605179A1 Expressing hepatitis b virus surface antigen for vaccine preparation
10/26/2006	CA2605165A1 Coccidial vaccine and methods of making and using same
10/26/2006	CA2605025A1 Viral nucleoprotein detection using an ion channel switch biosensor
10/26/2006	CA2605024A1 Covalent diabodies and uses thereof
10/26/2006	CA2605020A1 Method for treating inflammatory bowel disease (ibd) by an anti-cd20 antibody
10/26/2006	CA2604933A1 Methods and compositions for modulating and detecting wisp activity
10/26/2006	CA2604909A1 Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
10/26/2006	CA2604840A1 Stabilized anti-hepatitis b (hbv) antibody formulations
10/26/2006	CA2604732A1 Vaccine against pandemic strains of influenza viruses
10/26/2006	CA2604705A1 Porcine circovirus and helicobacter combination vaccines
10/26/2006	CA2604675A1 Diagnostic and therapeutic potential of immune globulin intravenous (igiv) products
10/26/2006	CA2604604A1 Methods for treating and preventing fibrosis by il-21 / il-21r antagonists
10/26/2006	CA2604515A1 Toll-like receptor 14 (tlr14 ) and use thereof
10/26/2006	CA2604432A1 Novel vaccine formulations
10/26/2006	CA2604393A1 Methods and compositions for treating or preventing cancer
10/26/2006	CA2604238A1 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
10/26/2006	CA2602635A1 Method of altering the binding specificity of proteins by oxidation-reduction reactions
10/26/2006	CA2574572A1 Modulation of cytokine signaling regulators and applications for immunotherapy
10/25/2006	EP1715064A1 Nucleotide sequences derived from the genomes of the retroviruses HIV-1, HIV-2 and SIV, and their application to the amplification of these viral genomes and to the in vitro diagnosis of infections resulting from these viruses
10/25/2006	EP1715047A2 Recombinant mutants for inducing specific immune responses
10/25/2006	EP1715046A2 New polypeptide, DNA encoding the polypeptide, recombinant vector bearing the DNA and recombinant virus utilizing the recombinant vector as well as use thereof
10/25/2006	EP1715045A2 Recombinant antibodies for human therapy
10/25/2006	EP1715043A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
10/25/2006	EP1715042A1 EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRCITED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME
10/25/2006	EP1715038A1 Antibody targeting osteoclast-associated protein
10/25/2006	EP1715035A2 Synthetic polynucleotides encoding lysyl oxidase
10/25/2006	EP1714981A2 Method for the identification of antigenic peptides
10/25/2006	EP1714980A1 Human receptor proteins, related reagents and methods
10/25/2006	EP1714974A2 HIV-1-and HIV-2-peptides for inhibition of membranes fusion-associated events, including HIV transmission
10/25/2006	EP1714969A2 Immunostimulatory nucleic acid molecules
10/25/2006	EP1714154A2 Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
10/25/2006	EP1714152A2 Monoclonal antibody based biomarker discovery and development platform
10/25/2006	EP1713929A2 Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
10/25/2006	EP1713927A2 Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps)

1 ... 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 ... 1823